New prostate cancer treatment option at LHSC

London Health Sciences Centre (LHSC) is the first hospital in Canada to treat a patient with a new prostate cancer therapy.

Doctors say the Pluvicto medical isotope selectively targets cancerous cells while leaving other cells alone.

The therapy is now funded through the province as a standard treatment option people battling the advanced stages of the disease.

Nuclear Medicine Physician with LHSC Dr. David Laidley hopes that, “With the message going out, we’ll start seeing London and other centres offering this treatment and getting referrals for this treatment and hopefully slowing the disease as well as improved quality of life and improved outcomes.”